Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Genentech
Biotech
Eye disease biotech launches with $100M, Roche rival in clinic
Ollin Biosciences has already enrolled 150 patients in a phase 1b trial pitting its bispecific antibody against Roche's blockbuster eye med Vabysmo.
Darren Incorvaia
Sep 17, 2025 6:30am
Genentech pens $420M deal for Omass' preclinical IBD program
Sep 2, 2025 3:00am
Roche sees Alnylam RNAi drug flunk trial, still plans phase 3
Sep 1, 2025 4:39am
Genentech scraps $2B cell therapy pact with Adaptive
Aug 18, 2025 2:40pm
Bicycle lays off staff as Genentech rides away from R&D pact
Aug 8, 2025 8:50am
Genentech cuts 87 more jobs in another round of HQ layoffs
Jul 23, 2025 10:33am
